Assessment of bone marrow status in diffuse B-cell large cell lymphoma: PET/CT capabilities
https://doi.org/10.33667/2078-5631-2020-38-14-20
Abstract
The aim of this work was to present the results of a retrospective study of 35 patients with morphologically diagnosed diffuse B-cell large cell lymphoma with bone marrow damage from 22 to 82 years old, median 63 years. There were 27 men and 8 women. After histological confirmation, all patients performed positron emission tomography combined with computed tomography with 18F-fluorodeoxyglucose (FDG PET/CT) followed by bone marrow trepanobiopsy. Specific bone marrow lesions were detected in 100% of cases with PET/CT and in 68.6% of cases with trepanobiopsy. Diffuse bone marrow damage was detected in 24 (68.6%) cases, focal – in 10 (28.6%) patients and in 1 (2.8%) patient – a mixed variant. The data obtained indicate the predominance of diffuse damage to the bone marrow. The statistical analysis established the value of the standardized maximum absorption coefficient of FDG SUVmax for bone marrow damage equal more than 3.58. Sensitivity was at 90% and a specificity was at 92%. The sensitivity of the PET/CT method is higher with focal lesions of the bone marrow than with diffuse. SUVmax was 10.26 ± 1.67 and 2.86 ± 0.09, respectively. The differences between them are significant (p < 0.0001). PET/CT is a non-invasive method of metabolic imaging allows you to assess the condition of the bone marrow and other extranodal symptoms
of the disease at the stage of diagnosis, treatment and follow-up. It can replace the traditional method of bone marrow biopsy with diffuse B-cell large cell lymphoma.
About the Authors
N. A. Ognerubov
Tambov State University n.a. G.R. Derzhavin
Russian Federation
Tambov
Russian Federation
Tambov
T. S. Antipova
Centre for Nuclear Medicine of PET-Technology Co.
Russian Federation
Tambov
Russian Federation
Tambov
A. V. Blokhin
Pathological and Anatomical Bureau
Russian Federation
Tambov
Russian Federation
Tambov
References
1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. Ca: A Cancer J. Clin. 2019, 69, 7–34.
2. GLOBOCAN2018: https://gco.iarc.fr/today/data/factsheets/cancers/34-Non-hodgkinlymphoma-fact-sheet.pdf.
3. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116 (2010): 3724–3734.
4. Ali Eser, Funda Pepedil Tanrikulu, Aslıhan Sezgin, Ayşe Tülin Tuğlular The Role of PET/CT to Detect Bone Marrow Involvement in Hodgkin Lymphoma//Bezmialem Science 2019; 7 (2): 95–100.
5. Degen C, Christen S, Rovo A, et al. Bone marrow examination: a prospective survey on factors associated with pain. Annals of Hematology 89 (2010): 619–624.
6. Bain BJ. Bone marrow biopsy morbidity and mortality: 2002 data. Clin Lab Haematol 26 (2004): 315–318.
7. Macintyre EA, Vaughan-Hudson B, Linch DC, Vaughan-Hudson G, Jelliffe AM: The value of staging bone marrow trephine biopsy in Hodgkin’s disease. Eur J Haematol 39: 66, 1987
8. Adams HJ, Kwee TC, Fijnheer R, Dubois SV, Nievelstein RA, de Klerk JM. Bone marrow FDG-PET/CT in Hodgkin lymphoma revisited: do imaging and pathology match? Ann Nucl Med. 2015 Feb; 29 (2): 132–7.
9. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под. ред. акад. И.В. Поддубной, акад. В.Г. Савченко. Москва, 2018. 356 с.
10. Newman JS, Francis IR, Kaminski MS, Wahl RL: Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology 190: 111, 1994.
11. Stroobans S, Dupont P, Verhoef G, Thomas J, Vleugels S, Bormans G, De Roo M, Boogaerts M, Morrtelmans L: Comparison of whole-body positron emission tomography and gallium-67 citrate imaging for staging of lymphoma. Blood 88: 228a, 1996 (abstr, suppl 1).
12. Vishnu P, Wingerson A, Lee M, et al. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography. Clinical Lymphoma Myeloma and Leukemia 17 (2017): 631–636.
13. Teagle AR, Barton H, Charles-Edwards E, et al. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy. Acta Radiologica 58 (2017): 1476–1484.
14. Cortes-Romera M, Sabate-Llobera A, Mercadal-Vilchez S, et al. Bone Marrow Evaluation in Initial Staging of Lymphoma. Clinical Nuclear Medicine 39 (2014): e46–e52.
15. Li Wang, Lili Lin, Xin Zhao, Kui Zhao, Jimin Shi J The value of 18F-FDG PET/CT in the Detection of Bone Marrow Involvement in Patients with Primary DLBCL Compared with Bone Marrow Biopsy. Cancer Sci Clin Ther 2019; 3 (4): 211–220.
16. Berthet L, Cochet A, Kanoun S, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med 54 (2013): 1244–1250.
17. Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005; 23 (21): 4643–51. Comment in: J Clin Oncol. 2005; 23 (21): 4577–80.
18. Muslimani AA, Farag HL, Francis S, et al. The Utility of 18-F-Fluorodeoxyglucose Positron Emission Tomography in Evaluation of Bone Marrow Involvement by Non-Hodgkin Lymphoma. American Journal of Clinical Oncology 31 (2008): 409–412.
19. Adams H.J.A., Kwee TC, Keizer B, et al. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 41 (2014): 565–574.
20. Tian R, Su M, Tian Y, et al. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions. Skeletal Radiol 38 (2009): 451–458.
21. Yumei Chen, Mingge Zhou, Jianjun Liu, Gang Huang Prognostic Value of Bone Marrow FDG Uptake Pattern of PET/CT in Newly Diagnosed Diffuse Large B-cell Lymphoma. Journal of Cancer 2018, Vol. 9. 2018; 9 (7): 1231–1238.
22. Hoh CK, Glaspy J, Rosen P, Dahlbom M, Lee SJ, Kunkel L, Hawkin RA, Maddahi J, Phelps ME: Whole-body FDG-PET imaging for staging of Hodgkin’s disease and lymphoma. J Nucl Med 38: 343, 1997.
23. Khan AB, Barrington SF, Mikhaeel NG, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood 2013; 122: 61–67.
24. Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer 2013; 119: 1195–1202.
Review
For citations:
Ognerubov N.A., Antipova T.S., Blokhin A.V. Assessment of bone marrow status in diffuse B-cell large cell lymphoma: PET/CT capabilities. Medical alphabet. 2020;(38):14-20. (In Russ.) https://doi.org/10.33667/2078-5631-2020-38-14-20
Views:
4022
Email this article 